This trial suggests that DAW2020 could be a viable treatment option for OSA patients when used in conjunction with atomoxetine.
1 Primary · 2 Secondary · Reporting Duration: 1 week
Active Control
Non-Treatment Group
18 Total Participants · 2 Treatment Groups
Primary Treatment: Atomoxetine and DAW2020 oral capsules · Has Placebo Group · Phase 1 & 2
Age 21 - 70 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Massachusetts | 100.0% |
18 - 65 | 100.0% |
Brigham and Women's Hospital | 100.0% |
Met criteria | 100.0% |